journal
MENU ▼
Read by QxMD icon Read
search

International Clinical Psychopharmacology

journal
https://www.readbyqxmd.com/read/28938233/no-apparent-association-between-bipolar-disorder-and-cancer-in-a-large-epidemiological-study-of-outpatients-in-a-managed-care-population
#1
Natan R Kahan, Barbara Silverman, Irena Liphshitz, Dan-Andrei Waitman, Itzhak Ben-Zion, Alexander M Ponizovsky, Abraham Weizman, Alexander Grinshpoon
An association between bipolar disorder (BD) and cancer risk has been reported. The purpose of this study was to investigate this association through linkage analysis of a national HMO database and a national cancer registry. All members of the Leumit Health Services (LHS) HMO of Israel from 2000 to 2012 were included. Members with a recorded diagnosis of BD and a record of at least one written or dispensed prescription for pharmacotherapy for treatment of BD were classified as patients with BD. We linked the LHS population with the Israel National Cancer Registry database to capture all cases of cancer reported...
September 21, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28906325/antidepressant-combination-versus-antidepressants-plus-second-generation-antipsychotic-augmentation-in-treatment-resistant-unipolar-depression
#2
Gabriella Gobbi, Maykel F Ghabrash, Nicolas Nuñez, John Tabaka, Jessica Di Sante, Marie Saint-Laurent, Stephen Vida, Theodore Kolivakis, Nancy Low, Pablo Cervantes, Linda Booij, Stefano Comai
Patients with treatment-resistant unipolar depression (TRD) are treated with antidepressant combinations (ADs) or with second-generation antipsychotics plus AD (SGA+AD) augmentation; however, the clinical characteristics, the factors associated independently with response to SGA+AD, and the outcome trajectories have not yet been characterized. We performed a naturalistic study on the latest stable trial (medication unchanged for about 3 months) in 86 TRD patients with resistance to at least two ADs trials, who received ADs (n=36) or SGA+AD (n=50) treatments...
September 12, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28832492/implications-of-infection-and-trends-of-antibiotic-prescribing-in-hospitalized-patients-diagnosed-with-serious-mental-illness
#3
Tammie Lee Demler, Kimberly B Mulcahy
Hospital-acquired infections have been recognized as a significant factor in increased morbidity and mortality across our health system. Unique to infections associated with inpatient psychiatric hospitalization is the additional hypothesized association of the role that antipsychotic agents and/or underlying disease may play in an increased risk for infection. In this paper, we explore the types of infections diagnosed in an inpatient psychiatric hospital, the demographics of the patients infected, and whether or not the patient was on antipsychotic agents at the time of infection...
August 21, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28817397/real-world-data-on-paliperidone-palmitate-for-the-treatment-of-schizophrenia-and-other-psychotic-disorders-a-systematic-review-of-randomized-and-nonrandomized-studies
#4
Robin Emsley, Eduard Parellada, Miquel Bioque, Berta Herrera, Teresa Hernando, Marta García-Dorado
The aim of this study was to perform a systematic review of the effects of 1-month paliperidone palmitate (PP1M) for the treatment of schizophrenia and related psychotic disorders in terms of outcomes reported in real-world evidence studies. A systematic review of real-world randomized and nonrandomized studies with PP1M was performed and is reported according to PRISMA guidelines. Comparative effectiveness data with oral antipsychotics indicate that PP1M has a lower likelihood of relapse-related events, including rehospitalization, and these differences are clinically relevant...
August 16, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28806194/paliperidone-palmitate-3-month-treatment-results-in-symptomatic-remission-in-patients-with-schizophrenia-a-randomized-multicenter-double-blind-and-noninferiority-study
#5
Adam J Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, David Hough, Maju Mathews
The current analysis assessed symptomatic and functional remission achieved following paliperidone palmitate 3-month (PP3M) versus 1-month (PP1M) treatment in patients (age: 18-70 years) with schizophrenia, previously stabilized on PP1M. Following a less than or equal to 3-week screening, and a 17-week, flexible-dosed, open-label phase [PP1M: day 1 (150 mg eq. deltoid), day 8 (100 mg eq. deltoid), weeks 5, 9, and 13 (50, 75, 100, or 150 mg eq., deltoid/gluteal)], clinically-stable patients were randomized (1 : 1) to PP3M (fixed-dose, 175, 263, 350, or 525 mg eq...
August 11, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28777129/aripiprazole-and-impulse-control-disorders-higher-risk-with-the-intramuscular-depot-formulation
#6
Unax Lertxundi, Rafael Hernandez, Juan Medrano, Saioa Domingo-Echaburu, Montserrat Garcia, Carmelo Aguirre
Dopamine agonists have been associated with an increased risk of developing impulse control disorders (ICDs). The US Food and Drug Administration (FDA) issued a safety warning in 2016 of a possible association between ICDs and aripiprazole. Recently, one large epidemiological study has confirmed this risk. In the present study, we aim to determine whether the safety signal of ICDs associated with aripiprazole detected by the FDA is replicated in the European pharmacovigilance database (EudraVigilance). We searched for all suspected spontaneous cases of ICDs associated with aripiprazole in EudraVigilance up to 23 February 2017...
August 2, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28763345/risk-of-hair-loss-with-different-antidepressants-a-comparative-retrospective-cohort-study
#7
Mahyar Etminan, Mohit Sodhi, Ric M Procyshyn, Michael Guo, Bruce C Carleton
The aim of this study was to quantify the risk of hair loss with different antidepressants. A retrospective cohort study design using a large health claims database in the USA from 2006 to 2014 was utilized. A cohort of new user and mutually exclusive users of fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, desvenlafaxine, and bupropion were followed to the first diagnosis of alopecia. The cohort was comprised of 1 025 140 new users of fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, desvenlafaxine, and bupropion, with sertraline the most commonly prescribed (N=190 227) and fluvoxamine (N=3010) the least prescribed...
July 31, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28763344/the-impact-of-fatigue-and-energy-on-work-functioning-and-impairment-in-patients-with-major-depressive-disorder-treated-with-desvenlafaxine
#8
David Sarfati, Vanessa C Evans, Edwin M Tam, Cindy Woo, Grant L Iverson, Lakshmi N Yatham, Raymond W Lam
Fatigue and low energy are cardinal symptoms of major depressive disorder (MDD) that have an impact on work functioning. Antidepressants with noradrenergic activity have been hypothesized to improve symptoms of fatigue and low energy. We examined the impact of these symptoms on work functioning in patients with MDD treated with the serotonin and noradrenaline reuptake inhibitor, desvenlafaxine. A secondary analysis was carried out from a study of employed adult outpatients (n=35) with MDD and subjective cognitive complaints treated with desvenlafaxine 50-100 mg/day for 8 weeks...
July 31, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28727644/cariprazine-specificity-profile-in-the-treatment-of-acute-schizophrenia-a-meta-analysis-and-meta-regression-of-randomized-controlled-trials
#9
Filippo Corponi, Alessandro Serretti, Stuart Montgomery, Chiara Fabbri
Cariprazine is a new dopamine D2 and D3 receptor partial agonist antipsychotic. Meta-analytic evidence of efficacy in acute schizophrenia and specific groups of patients is lacking. We carried out a meta-analysis in patients with acute schizophrenia to evaluate the efficacy of cariprazine over placebo and active comparators in overall symptoms, positive and negative symptoms and quality of life. Low and high (≥6 mg/day) doses were tested separately. The possible effect of clinical-demographic modulators was also tested...
July 19, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28704228/patient-attitudes-to-clozapine-initiation
#10
Siobhan H Gee, Sukhwinder S Shergill, David M Taylor
Clozapine is widely underused. No study has assessed views of patients suitable for, but not yet receiving, clozapine. We aimed to assess views of clozapine in patients eligible for clozapine but not yet prescribed it by conducting semistructured interviews with acutely unwell hospital in-patients. We interviewed 61 of 116 eligible patients and 50 (82%) answered all questions. At interview, 33 (54%) of 61 participants had heard of clozapine and 17 (30%) of 57 participants said they would take it if asked. Overall, 31 (57%) of 54 respondents said blood testing would not preclude them taking clozapine...
July 12, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28692485/safety-and-tolerability-of-cariprazine-in-patients-with-acute-exacerbation-of-schizophrenia-a-pooled-analysis-of-four-phase-ii-iii-randomized-double-blind-placebo-controlled-studies
#11
Willie Earley, Suresh Durgam, Kaifeng Lu, István Laszlovszky, Marc Debelle, John M Kane
Cariprazine, a potent dopamine D3 and D2 receptor partial agonist antipsychotic with preferential binding to D3 receptors, is Food and Drug Administration approved for treating schizophrenia and manic or mixed episodes of bipolar I disorder. A post-hoc safety/tolerability analysis of data from the four acute trials in the cariprazine schizophrenia clinical development program (NCT00404573; NCT00694707; NCT01104766; NCT01104779) was carried out using the overall safety population (all patients who received ≥1 dose of study drug) and modal daily dose subgroups (1...
July 7, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28657934/multitarget-botanical-pharmacotherapy-in-major-depression-a-toxic-brain-hypothesis
#12
Siu W Tang, Wayne H Tang, Brain E Leonard
A significant number of patients with major depression do not respond optimally to current antidepressant drugs. As depression is likely to be a heterogeneous disorder, it is possible that existing neurotransmitter-based antidepressant drugs do not fully address other pathologies that may exist in certain cases. Biological pathologies related to depression that have been proposed and studied extensively include inflammation and immunology, hypercortisolemia, oxidative stress, and impaired angiogenesis. Such pathologies may induce neurodegeneration, which in turn causes cognitive impairment, a symptom increasingly being recognized in depression...
June 27, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28617681/psychotropic-drugs-prescription-in-undocumented-migrants-and-indigent-natives-in-italy
#13
Cesare Cerri, Gianfrancesco Fiorini, Silvia Bini, Antonello E Rigamonti, Nicoletta Marazzi, Alessandro Sartorio, Silvano G Cella
To evaluate psychotropic drug use in undocumented migrants and natives in the same conditions of poverty. We studied drug dispensation by a nongovernmental organization during the year 2014. Drugs were identified according to the Anatomical Chemical Therapeutic classification and their quantity was measured in defined daily doses (DDD). We determined the percentage of patients taking at least one medicine with psychotropic activity in relation to the total number of patients receiving medicines of any class...
September 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28598899/long-term-function-and-psychosocial-outcomes-with-venlafaxine-extended-release-75-225%C3%A2-mg-day-versus-placebo-in-the-prevent-study
#14
Koichiro Watanabe, Michael E Thase, Toshiaki Kikuchi, Takashi Tsuboi, Yuko Asami, Elizabeth Pappadopulos, Min Zhang, Matthieu Boucher, Susan Kornstein
This post-hoc analysis evaluated long-term psychosocial outcomes in patients with recurrent major depressive disorder treated with venlafaxine extended release (ER) 75-225 mg/day or placebo. Patients who responded to 10-week venlafaxine ER 75-300 mg/day treatment and maintained response through a 6-month continuation treatment were assigned randomly to venlafaxine ER or placebo maintenance-phase treatment. Data from responders to acute and continuation venlafaxine ER 75-225 mg/day treatment were analyzed during 12-month maintenance treatment while receiving venlafaxine ER of up to 225 mg/day...
September 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28542035/trends-and-factors-associated-with-antipsychotic-use-among-elderly-patients-with-dementia-in-taiwan-from-2005-to-2013-a-population-based-study
#15
Yu-Wen Chiu, Chih-Wan Huang, Pei-Jung Chen, Nan-Wen Yu, Hui-Ju Tsai, Chi-Shin Wu, Chia-Ming Chang
This study aimed to examine the trends and factors associated with antipsychotic prescriptions for elderly outpatients with dementia in Taiwan from 2005 to 2013. We assessed the annual prescription patterns of antipsychotic medications among elderly patients attending outpatient visits for dementia between 2005 and 2013 using the National Health Insurance Research Database in Taiwan. We also carried out logistic regression analyses to test the trends and associated factors. We found that any antipsychotic prescriptions for elderly patients making visits for dementia increased slightly, from 25...
September 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28542034/dopamine-d2-receptor-affinity-of-antipsychotics-in-relation-to-subjective-well-being-in-patients-with-a-psychotic-disorder
#16
Iris E de Wit, Floor A van Dijk, Carin J Meijer, Mirjam J van Tricht, Lieuwe de Haan
Dopamine D2-receptor blockade by antipsychotic medication reduces psychotic symptoms, but may reduce subjective well-being. The current study aims to further explore the relation between dopamine D2-receptor affinity and subjective well-being within a large sample of patients with psychotic disorders. Patients participated in a longitudinal naturalistic cohort study: the Genetic Risk and Outcome of Psychosis (GROUP) study. Three groups of antipsychotic medication were created on the basis of their affinity for the D2-receptor: (i) loose or partial agonistic binding, (ii) moderate binding, and (iii) tight binding...
September 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28538024/effects-of-vilazodone-on-suicidal-ideation-and-behavior-in-adults-with-major-depressive-disorder-or-generalized-anxiety-disorder-post-hoc-analysis-of-randomized-double-blind-placebo-controlled-trials
#17
Michael E Thase, John Edwards, Suresh Durgam, Changzheng Chen, Cheng-Tao Chang, Maju Mathews, Carl P Gommoll
Treatment-emergent suicidal ideation and behavior are ongoing concerns with antidepressants. Vilazodone, currently approved for the treatment of major depressive disorder (MDD) in adults, has also been evaluated in generalized anxiety disorder (GAD). Post-hoc analyses of vilazodone trials were carried out to examine its effects on suicidal ideation and behavior in adults with MDD or GAD. Data were pooled from vilazodone trials in MDD (four studies) and GAD (three studies). The incidence of suicide-related events was analyzed on the basis of treatment-emergent adverse event reporting and Columbia-Suicide Severity Rating Scale (C-SSRS) monitoring...
September 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28492411/advanced-glycation-end-products-among-patients-maintained-on-antipsychotics
#18
Samer Hammoudeh, Suhaila Ghuloum, Ziyad Mahfoud, Arij Yehya, Dennis Mook-Kanamori, Marjonneke Mook-Kanamori, Karsten Suhre, Abdulmoneim Abdulhakam, Azza Al-Mujalli, Yahya Hani, Reem El Sherbiny, Hassen Al-Amin
The aim of this study was to measure advanced glycation end products (AGEs) among participants maintained on antipsychotics using the AGE Reader and to compare them with controls from the general population. Participants maintained on antipsychotics for at least 6 months were recruited from the Psychiatry Department at Rumailah Hospital, Doha, Qatar. Healthy controls were recruited from the primary healthcare centers in Doha, Qatar. AGEs of a total of 86 participants (48 patients and 38 controls) were recorded...
September 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28430670/comparison-between-long-acting-injectable-aripiprazole-versus-paliperidone-palmitate-in-the-treatment-of-schizophrenia-systematic-review-and-indirect-treatment-comparison
#19
Chi-Un Pae, Sheng-Min Wang, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Alessandro Serretti, Robin Emsley
We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia. Extensive databases searches on short-term, placebo-controlled, randomized studies of AOM and PP were performed. Indirect treatment comparisons were performed between the two long-acting injectable antipsychotics (LAIAs). The primary efficacy endpoint was the mean change in the Positive and Negative Syndrome Scale total score from baseline between each LAIA and placebo...
September 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28368900/the-effect-of-methylphenidate-on-anxiety-and-depression-symptoms-in-patients-with-asperger-syndrome-and-comorbid-attention-deficit-hyperactivity-disorder
#20
Pavel Golubchik, Michal Rapaport, Abraham Weizman
The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD). A group of 12 patients with AS/ADHD, aged 8-18 years, received 12 weeks of MPH treatment. The severities of ADHD, anxiety, and depression symptoms were assessed by means of the ADHD Rating Scale (ADHD-RS), Screen for Child Anxiety Related Emotional Disorders, and the Children's Depression Inventory...
September 2017: International Clinical Psychopharmacology
journal
journal
29324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"